



Expert UK-based CRO offering customised bioassay development, pharmacological profiling and compound screening

Welcome to the latest edition of our newsletter

As the fight against COVID-19 is still on, we would like you to know that Aurelia Bioscience's labs are operational as usual and we are taking full precautionary measures as per the UK government's policy. Whilst we go through these unusual times together, here are some updates from our last quarter:

Advancing Targeted Protein Degradation Research with Automated Western Blotting

Our CEO, Dr. Gary Allenby shared his experience working with Bio-Techne's Simple Western technology ([WES and JESS](#)) for protein degradation studies in a webinar earlier this month. If you missed the webinar, but are interested in the topic, [follow the link to watch the recording:](#)
https://www.proteinsimple.com/webinar_simple_western.html#sw22



New member: Ryan Mordue, Senior Research Scientist

Ryan is the newest addition to the Aurelia Bioscience family and will primarily be involved in bioassay development and compound screening for client projects. After completing his PhD in RNA binding proteins and modulation of protein synthesis following stress, he went on to do a post-doc in cell signalling. He loves working in the lab and finding solutions to scientific challenges. His naturally curious nature and love for biology inspired him to be a scientist in the first place.



Outside of work, Ryan enjoys playing rugby and has a flair for technology (and therefore, has happily volunteered to help the team with all tech related problems!). “It is very inspiring to be a part of a small, but really experienced team...I am looking forward to getting more and more involved in the projects”, says an enthusiastic Ryan as he poses for a picture for our quarterly newsletter!

Video: Kinase Target Engagement

Do you want to evaluate your compound binding against a panel of kinases in a cellular environment? Do you want to understand the kinetic profile of your compound? Are you aware of how selective your compound is or how it behaves in a physiological environment (e.g. ATP concentration)? If the answer to any of these questions is important to your kinase discovery programme, then we might just have the perfect solution for you!

Aurelia Bioscience offers [kinase compound profiling services](#) using Target Engagement (TE) Intracellular Kinase Assays. Using Promega’s NanoBRET™ technology, we have implemented intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells. [Follow the link to watch a video on this amazing technology!](#) : <https://youtu.be/tAQRTVSuruE>

aurelia bioscience
bioassays + screening

Kinase Compound Profiling

re-energise your kinase discovery programme

"helping you discover the next breakthrough drug"

Do you want to understand the kinetic profile of your compound?

Using Promega's NanoBRET™ technology, our target engagement assays can:

- Profile compound binding in live cells
- Express full-length kinase target in cells
- Evaluate compound binding at physiological ATP

GET IN TOUCH WITH US

BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, United Kingdom
info@aureliabio.com | www.aureliabio.com
/Aureliabio | +44(0)1158370503

Contact Information:

Aurelia Bioscience
BioCity Nottingham,
Pennyfoot Street,
Nottingham NG1 1GF
United Kingdom

Phone: +44 (0)115 837 0503

Email: info@aureliabio.com

Web: <https://www.aureliabio.com>